Ariad’s New Drug Application of Brigatinib for NSCLC to Be Reviewed by FDA
News
The U.S. Food and Drug Administration (FDA) will review Ariad‘s new drug application (NDA) for brigatinib, an investigational therapy for patients with non-small cell lung cancer (NSCLC) who have progressed following ... Read more